Yahoo
NasdaqCM - Delayed Quote USD

Sunshine Biopharma, Inc. (SBFMW)

0.0255 0.0000 (0.00%)
At close: October 30 at 9:38:10 AM EDT
Chart Range Bar
Loading chart for SBFMW
  • Previous Close 0.0255
  • Open 0.2428
  • Bid --
  • Ask --
  • Day's Range 0.0255 - 0.0255
  • 52 Week Range 0.0255 - 0.0255
  • Volume 0
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.52
  • PE Ratio (TTM) --
  • EPS (TTM) -2.2140
  • Earnings Date --
  • Forward Dividend & Yield --
  • 1y Target Est --
  • Moby Rating Neutral

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

sunshinebiopharma.com

50

Full Time Employees

--

Fiscal Year Ends

--

Sector

--

Industry

Recent News

View More

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 9.26M
Earnings -1.56M
Profit Margin -16.88%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-2M
0
2M
4M
6M
8M
-20.0%
-15.0%
-10.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -16.50%

  • Return on Assets (ttm)

    -9.91%

  • Return on Equity (ttm)

    -21.92%

  • Revenue (ttm)

    35.35M

  • Net Income Avi to Common (ttm)

    -5.83M

  • Diluted EPS (ttm)

    -2.2140

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.03M

  • Total Debt/Equity (mrq)

    2.46%

  • Levered Free Cash Flow (ttm)

    -2.01M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: